The debate about two studies showing that, with few genetic mutations, H5N1 bird flu strains could become more easily transmissible among ferrets, a laboratory model for humans, “has become a debate about the role of science in society. Two questions should be addressed here: should this type of research be conducted at all; and if so, should all data generated by this research be published?” Ab Osterhaus, head of the Institute of Virology, at Erasmus Medical Centre in Rotterdam, writes in a Guardian opinion piece. A team from Erasmus conducted one of the two studies, he notes.
Keiji Fukuda, WHO assistant director-general for health security and environment, “is hoping bird flu studies currently in publishing limbo will be released by the time the agency hosts a second meeting on the controversy this summer,” the Canadian Press/Winnipeg Free Press reports. “A major break in the impasse would be needed for that to happen,” the Canadian Press writes, adding, “As things currently stand, revised versions of the two studies are due to be presented late this month to the U.S. biosecurity panel that earlier recommended against their full publication.”
U.S. Clinical Trials Show Single Dose Of H1N1 Vaccine Protects Pregnant Women, Children Under 10 Need Two Doses
U.S. government data released on Monday confirmed that a single dose of the vaccine protects pregnant women from the virus, while children under the age of 10 years need two doses of the vaccine, the Washington Post reports. The findings came the same day that a team of experts tasked with monitoring the national H1N1 vaccine campaign for any adverse side effects met for the first time.
A WHO official on Tuesday backed the Afghan government’s decision to declare H1N1 (swine flu) a health emergency, forcing the closure of all schools in the country for three weeks in an effort to contain the virus, IRIN reports. H1N1 has reportedly infected over 300 people, resulting in two deaths.
The WHO is looking into reports that patients with “severely suppressed immune systems” in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.
Drugmaker GlaxoSmithKline announced plans on Tuesday to donate 50 million doses of its H1N1 (swine flu) vaccine to the WHO for use in developing countries within the next few months, Reuters reports.
Despite reports that the numbers of new H1N1 (swine flu) are leveling off in some parts of the Northern Hemisphere, the virus continues to spread, the WHO said Friday, Reuters reports. “In an update on the H1N1 swine flu virus, the WHO said parts of the southern and southeastern United States, as well as Iceland and Ireland, seemed to have weakening levels of disease after an unusually early start of the winter flu season,” the news service writes.
Ahead of the anticipated CDC release of revised U.S. H1N1 (swine flu) death toll estimates, Reuters examines how the agency and WHO measure the impact of the virus, after both organizations “stopped trying to count actual cases months ago, once it became clear that H1N1 was a pandemic that would infect millions.”
U.S. health officials briefing Congress on Wednesday would not outline a timeframe for when enough H1N1 (swine flu) vaccines would be available to reach all high-risk populations in the country, the Washington Post reports.
Noting that the journal Science last week published the second of two controversial bird flu research papers, in which a team led by Ron Fouchier of the Erasmus Medical Center in Rotterdam created a mutated strain of the virus that spreads easily among ferrets, a Washington Post editorial writes that “this is not the end of the story. Rather, it marks the beginning of an important chapter for both science and security.” The editorial continues, “The United States and other nations need a more sophisticated process for vetting research for possible security threats without discouraging or impairing scientists,” adding, “This is more difficult than it sounds.”